Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

HIV Clinical Trials

Volumn 11, Issue 4, 2010, Pages 197-204

  Vispo, Eugenia ^a   Barreiro, Pablo ^a   Maida, Ivana ^a   Mena, Alvaro ^a   Blanco, Francisco ^a   Rodríguez Novoa, Sonia ^a   Morello, Judit ^a   Jimenez Nacher, Inmaculada ^a   Gonzalez Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

antiretroviral therapy; HIV; integrase inhibitors; once daily; raltegravir; switch strategy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES;

EID: 78049451176     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1104-197     Document Type: Article

References (22)

1. Steigbigel R, Cooper D, Kumar P, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359: 339-354.
2. Wittkop L, Breilh D, Da Silva D, et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy. J Antimicrob Chemother. 2009;63:1251-1255.
3. Lennox J, De Jesus E, Lazzarin A, et al. Safety and effi cacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
4. Markowitz M, Nguyen B, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defi c Syndr. 2009;52: 350-356.
5. Grant P, Palmer S, Bendavid E, et al. Switch from enfu-virtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol. 2009;46:305-308.
6. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed mul-tidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis. 2009;49:1259-1267.
7. Talbot A, Machouf N, Thomas R, et al. Switch from enfu-virtide to raltegravir in patients with undetectable viral load: effi cacy and safety at 24 weeks in a Montreal cohort. J Acquir Immune Defi c Syndr. 2009;51:362-364.
8. Towner W, Klein D, Kerrigan H, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegra-vir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defi c Syndr. 2009;51:367-373.
9. Eron J, Young B, Cooper D, et al. Switch to a ralte-gravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
10. Markowitz M, Morales-Ramirez J, Nguyen B, et al. Anti-retroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defi c Syndr. 2006;43:509-515.
11. Iwamoto M, Wenning L, Petry A, et al. Safety, tolerabil-ity, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83:293-299.
12. McSharry J, Weng Q, Kulaway R, Drusano G. Dose range and dose fractionation studies for raltegravir pharmaco-dynamics in an in vitro hollow fi ber infection model system. In: Program and abstracts of the Tenth International Workshop on Clinical Pharmacology of HIV Therapy; April 15-17, 2009; Amsterdam. Abstract O-09.
13. Hluhanich R, Kinkade A, Wang M, Geleziunas R, Miller M, McColl D. HIV integrase inhibitors do not exert a post-antibiotic effect despite slow dissociation from integrase-DNA complexes in vitro. In: Program and abstracts from the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, CA. Abstract H-930.
14. Lanzafarme M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once daily dose enough? J Antimicrob Chemother. 2010;65:595-597.
15. Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. To p HIV Med. 2009;17:138-145.
16. Garrido C, Geretti A, Zahonero N, et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother. 2010;65:320-326.
17. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Updated December 1, 2009. http://aidsinfo. nih.gov.
18. Garrido C, de Mendoza C, Soriano V. New therapeutic strategies for raltegravir. J Antimicrob Chemother. 2010;65:218-223.
19. Martínez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection N Engl J Med. 2003. 349: 1036-1046.
20. Lima V, Gill V, Yip B, Hogg R, Montaner J and Harrigan R. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy. J Infect Dis. 2008;198:51-58.
21. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
22. Vispo E, Mena A, Maida I, et al. Hepatic safety profi le of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother. 2010;65:543-547.